CGEM Stock Overview
Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Cullinan Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$18.89 |
52 Week High | US$20.62 |
52 Week Low | US$7.64 |
Beta | 0.33 |
1 Month Change | 11.58% |
3 Month Change | 45.31% |
1 Year Change | 88.52% |
3 Year Change | -43.14% |
5 Year Change | n/a |
Change since IPO | -36.84% |
Recent News & Updates
Recent updates
Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth
Apr 23Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years
Sep 22Cullinan Oncology: One Of The Leaders In Cancer Treatment Development
Sep 14Cullinan Oncology grants stock options for 125.7K shares
Sep 02Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth
Jun 24Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation
Mar 05Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth
Oct 08Cullinan Oncology: Hub-And-Spoke Business Model For Drug Development
Jun 30Cullinan Oncology (CGEM) Presents At 2021 ASCO Annual Virtual Meeting - Slideshow
Jun 05Cullinan initiated Buy at H.C. Wainwright on pipeline strength
Feb 02Shareholder Returns
CGEM | US Biotechs | US Market | |
---|---|---|---|
7D | 5.6% | 1.0% | 1.2% |
1Y | 88.5% | 0.7% | 24.9% |
Return vs Industry: CGEM exceeded the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: CGEM exceeded the US Market which returned 24.7% over the past year.
Price Volatility
CGEM volatility | |
---|---|
CGEM Average Weekly Movement | 10.2% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CGEM's share price has been volatile over the past 3 months.
Volatility Over Time: CGEM's weekly volatility (10%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2016 | 85 | Nadim Ahmed | cullinantherapeutics.com |
Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company’s lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.
Cullinan Therapeutics, Inc. Fundamentals Summary
CGEM fundamental statistics | |
---|---|
Market cap | US$717.90m |
Earnings (TTM) | -US$153.16m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.3x
P/E RatioIs CGEM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CGEM income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$153.16m |
Earnings | -US$153.16m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -3.56 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did CGEM perform over the long term?
See historical performance and comparison